Therapeutics and Prophylaxis - HAN
Breadcrumb
Jump To:
New COVID-19 Therapeutics Announcements
- Nov 8, 2023: Paxlovid thresholds for all entities will be set to zero on Nov. 27; Ordering will be available using the out-of-cycle process until Dec 15
- Oct. 20, 2023: Preparing for USG Procured COVID-19 Therapeutics to Transition to the Commercial Market: A New Transition Guide
- Sept 29, 2023: Lagevrio Transition to Traditional Commercial Distribution
- Sept 13, 2023: At-Home Test to Treat Program - Telehealth Initiative Gives Quick Access to Free Lifesaving COVID-19 Treatments
- Sept 11, 2023: FDA Approved and Authorized Updated mRNA COVID-19 Vaccines; Bivalent mRNA COVID-19 Vaccines Are No Longer Authorized
Overview of COVID-19 Therapeutics and Prophylaxis for Non-Hospitalized Patients
The resources below provide:
- Interim guidance on outpatient treatment decisions for patients at risk of developing severe COVID-19.
- Comparison table of treatment options.
- How providers may obtain these treatments or prophylaxis for their patients.
- Where providers can refer their patients for infusion therapies.
- Reporting requirements.


Treatment
*Adapted from COCA call 1/22/22
Clinicians should refer to the EUA healthcare provider fact sheets for further details on Paxlovid, remdesivir, and molnupiravir. For the FDA-approved remdesivir (Veklury) for 12 yrs and older weight at least 40kg, refer to the full prescribing information.
Clinicians should refer to the EUA healthcare provider fact sheets for further details on Paxlovid, remdesivir, and molnupiravir. For the FDA-approved remdesivir (Veklury) for 12 yrs and older weight at least 40kg, refer to the full prescribing information.
Prophylaxis
IMPORTANT UPDATE 1/26/2023: Evusheld is not currently authorized by the FDA for emergency use in the U.S.
Description |
|
Patient Profiles |
|
Become a Provider
HHS currently distributes an allocation of Paxlovid and Molnupiravir to each state. All medications must be ordered through the Health Partners Order Portal (HPOP).
- Sign up with HPOP here.
- If you need help getting set up, email DPH.MABTherapy@illinois.gov
Locate Therapeutics and Prophylaxis In The City
- Infusion Providers Accepting External Referrals:
AMITA Health Saints Mary and Elizabeth Medical Center | Tel: 312-770-8534 Fax: 312-770-3182 |
John H Stroger Jr Hospital of Cook County | covidtherapeutics@cookcountyhhs.org |
Provident Hospital of Chicago | covidtherapeutics@cookcountyhhs.org |
Saint Anthony Hospital | ttruesdell@sahchicago.org |
Swedish Covenant Hospital | Tel: 773-907-7700 |
- Test to Treat in Chicago
- Providers who don’t want to receive allocations can use the ASPR COVID-19 Therapeutics Locator to find providers, pharmacies and infusion centers with doses on hand.
- For providers looking for immediate access to COVID-19 Therapeutics, available doses may be found on the IDPH Matchmaker Site. If you are a provider and have extra doses in between distribution cycles, please use this site so others have access.
State and Federal Reporting Requirements
Reporting into Health Partner Ordering Portal (HPOP)
Reporting into HHS Teletracking - All therapeutics that require reporting into this portal are currently paused.
- Report utilization and doses on hand of Paxlovid and Legevrio at least twice a month by 11:59ET pm on the 15th and last day of the month. Report on hand doses of all other therapeutics once a month by 11:59ET pm the last day of the month.
- When reporting utilization of each product, report the quantity used since the last report. Do not report the cumulative amount over time.
- For any issues related to ordering or reporting of HPOP therapeutics, reach out to cars_helpdesk@cdc.gov or 833-748-1979
- Click here (https://aspr.hhs.gov/COVID-19/Therapeutics/Distribution/Pages/process-for-ordering.aspx) for more information on HPOP reporting.
Reporting into HHS Teletracking - All therapeutics that require reporting into this portal are currently paused.
- Instructions for Completion (https://www.cdc.gov/nhsn/pdfs/covid19/ltcf/57.158-toi-508.pdf)

Provider Resource Library and Other Useful Links
- Webinars
- Research
- MMWR: Information for Persons Who Are Immunocompromised Regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages
- MMWR: Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities and Healthcare Systems
- CDC MMWR: Hospitalization and ED Encounters for COVID-19 After Paxlovid Treatment
- MMWR: Equitable Dispensing of COVID-19 Oral Antivirals
- MMWR: Racial and Ethnic Disparities in Outpatient Treatment of COVID-19
- MMWR: Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years
- Educational Tools
- Side-by-Side Overview of COVID-19 Therapeutics Authorized or Approved
- NIH COVID-19 Treatment Guidelines
- COVID-19 Treatment Guidelines and Considerations for the Immunocompromised
- Clinical Considerations for COVID-19 Treatment in Outpatients
- ASPR Paxlovid Info Sheet
- Paxlovid Drug interactions
- FDA Updated Paxlovid Fact Sheet
- NIH Paxlovid Checklist Tool for Prescribers
- FDA Paxlovid Patient Eligibility Screening Checklist Tool for Prescribers
- FDA Updated Lagevrio Fact Sheet
- Lagevrio Information Sheet
- Veklury (remdesivir) Prescribing Information
- COVID-19 Drug Interactions Checker App
- Underlying Medical Conditions Associated With Higher Risk for Severe Covid-19
- Paxlovid FDA Letter of Authorization, updated November 1, 2023
- Printable Posters
- Other Links
- Maintaining Access to COVID-19 Care for the Uninsured: HHS Bridge Access Program
- Fact Sheet: COVID-19 Public Health Emergency Transition Roadmap
- IDPH Covid-19 Therapeutics Consumer Experience Survey
- HHS Secretary Becerra renewed the COVID-19 Public Health Emergency Declaration for 90 days (7/15/2022)
- FDA Authorizes Pharmacists to Prescribe Paxlovid
- Bebtelovimab and Evushed EUA retain neutralization against all circulating variants
Shelf life Extensions
Shelf-Life Extension infomation. Click the links to view the affected lot numbers.
New! Searchable database of COVID-19 Therapeutic Product Expiration Dates is now available
New! Searchable database of COVID-19 Therapeutic Product Expiration Dates is now available
- Evusheld
- Paxlovid
- Lagevrio
- Bebtelovimab
- Sotrovimab
- Guidelines for Product Return: Bamlanivimab, BAM/ETE, REGEN-COV, Sotrovimab
Sites interested in providing USG-purchased COVID-19 therapeutics, sign up for the Health Partners Ordering Portal here
TREAT COVID-19
The Chicago Department of Health has partnered with the Chicago Internal Medicine Practice and Research (CIMPAR S.C.) for the TREAT COVID-19 program. CIMPAR S.C. will provide onsite mobile treatment and infection prevention services to LTCF residents of Medicare/Medicaid certified nursing homes and assisted living facilities who test positive for Covid-19. See flyer for details